Phase II Clinical Trial of the Epothilone B Analog, Ixabepilone, in Patients With Non Small-Cell Lung Cancer Whose Tumors Have Failed First-Line Platinum-Based Chemotherapy

摘要: Purpose Ixabepilone is the first in a new class of antineoplastic agents, epothilones and their analogs. This international, randomized, phase II trial assessed two administration schedules ixabepilone as second-line therapy patients with non–small-cell lung cancer (NSCLC). Patients Methods had experienced disease progression after one prior cisplatin- or carboplatin-based chemotherapy regimen. was administered single 32 mg/m2 3-hour infusion (77 patients; arm A) 6 1-hour daily for 5 consecutive days (69 B) 3-week cycle. Results The intent-to-treat objective response rate 14.3% A 11.6% B. Median duration 8.7 months (95% CI, 5.3 to 9.5 months) 9.6 6.1 19.7 time 2.1 1.4 2.8 1.5 survival 8.3 5.8 11.5 mon...